4th Quarter - Report — ARENTFOX SCHIFF LLP for ALLERGAN PLC (2014)

Firm

ARENTFOX SCHIFF LLP

Client

ALLERGAN PLC

Income

$70,000

Expenses

—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Lobbyist	Covered position, as disclosed
ROBERT BENNETT New	U.S. Senator
JON BOUKER	—
AMY DEMSKE	—
PHILIP ENGLISH	—
DAN RENBERG	—

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Bills named: H.R. 672 (113th)

Medicare/Medicaid MMM

Medicare reimbursements for oncology drugs

Lobbyist	Covered position, as disclosed
AMY DEMSKE	—
PHILIP ENGLISH	—

Contacted: Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Trans-Pacific Partnership (TPP) intellectual property protection and policy

Lobbyist	Covered position, as disclosed
JON BOUKER	—
PHILIP ENGLISH	—

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Copyright/Patent/Trademark CPT

S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting

Lobbyist	Covered position, as disclosed
AMY DEMSKE	—
PHILIP ENGLISH	—

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: S. 1720 (113th), S. 1013 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.